Skip to main content

Month: February 2022

StrikeForce Expands Into Brazil with New Distribution Partner

EDISON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — StrikeForce Technologies, Inc. (OTCQB: SFOR), a cyber security company that provides next-gen cyber, privacy & data protection solutions for consumers, corporations, & government agencies, announced today a new Reseller/Distributor agreement with Zentek corporation. “We are really excited about this announcement,” says Will Lynch, Director of Channel Distribution for StrikeForce, “Zentech provides an IT marketplace for Banks, Insurance carriers, Financial Services firms and ISPs, and they have been asked to integrate our GuardedID and MobileTrust into a bundle of services within an Insurance Company’s Personal Cyber Insurance policy. The initial launch is expected towards the end of Q2 into Q3”. “Brazil has one of the strongest economies in Latin America. Due to that fact,...

Continue reading

Troika Media Group to Acquire Converge Direct LLC, a Leading Digital and Offline Performance Media and Marketing Company, for $125 Million

Los Angeles, CA, Feb. 24, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Troika Media Group, Inc. (Nasdaq:TRKA): Financial Highlights: Converge Direct, LLC and its affiliated businesses (collectively, “Converge”) generated approximately $300 million of revenue and $23 million of adjusted EBITDA for the year ended December 31, 2021. Estimated combined adjusted EBITDA over $27 million for CY 2022. Significantly accretive to adjusted earnings per share.  Following the closing, it is anticipated that the majority of the combined business’ revenue will be recurring. Increased margins per customer relationship without a significant increase in operating costs with positive client outcomes arising from deeper client engagements. Consolidated cost synergies of more than $2 million expected in the first year after closing. Cantor Fitzgerald...

Continue reading

Man Group PLC : Form 8.3 – John Menzies plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Man Group PLC(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree John Menzies plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

Continue reading

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (Nasdaq: FOLD) (“Amicus”) to terminate their previously announced Business Combination Agreement (the “Business Combination Agreement”), effective immediately.   “While this is not the outcome we had hoped for, ARYA IV still has over a year remaining to identify and execute on a business combination transaction and the ARYA IV team believes it is well positioned to identify and execute on an opportunity that meets its key investment criteria and that can deliver value for its shareholders within that time period,” said Adam Stone,...

Continue reading

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022 Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; interim data readout from Helia extension study of ultevursen planned by year-end 2022 Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial data from molecular proof-of concept biomarker study for QR-504a for Fuchs endothelial corneal dystrophy to be reported in 2022 Cash runway into mid-to-late 2024LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the...

Continue reading

Duluth Holdings Inc. to Report Fourth Quarter 2021 Financial Results on March 10

MOUNT HOREB, Wis., Feb. 24, 2022 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s casual wear, workwear and accessories, today announced that it will report fourth quarter 2021 financial results before market on Thursday, March 10. 2022. A conference call and audio webcast with analysts and investors will be held on Thursday, March 10, 2022 at 9:30 am Eastern Time, to discuss the results and answer questions. Live conference call: 844-875-6915 (domestic) or 412-317-6711 (international)Conference call replay available through March 17, 2022: 877-344-7529 (domestic) or 412-317-0088 (international)Replay access code: 9177748 Live and archived webcast: ir.duluthtrading.com To expedite entry into the call and avoid waiting for a live operator,...

Continue reading

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments. To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 5058194. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint...

Continue reading

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting – – Pre-clinical Data on CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted for Presentation at the AACR Annual Meeting – – CFT8634 Phase 1/2 Clinical Trial in Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors Expected to Initiate in 1H 2022; CFT1946 IND Application Submission and Phase 1 Trial Initiation Expected in 2H 2022 – – Year-end Cash, Cash Equivalents and Marketable Securities Expected to Provide Runway to End of 2024 – WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

Continue reading

Microbix Announces Issuance of Stock Options

Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, Ontario, Feb. 24, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In consultation with the CEO, CFO, and COO, Microbix’s Board of Directors has approved the issuance of 2,805,000 options in accordance with the terms of the Stock Option Plan. These approved options are exercisable at a price of $0.60 per share, as determined by the closing price of the TSX on 18 February, 2022. Each option will vest and be exercisable after...

Continue reading

CE Brands Reports Third Quarter 2022 Financial Results and Announces Shareholder Update Call

CALGARY, Alberta, Feb. 24, 2022 (GLOBE NEWSWIRE) — CE Brands Inc. (TSXV: CEBI; CEBI.WT) (“CE Brands”, “we”, “our”, or the “Company”), a data-driven consumer-electronics company, today announced its financial results for the three-month and nine-month periods ended December 31, 2021 (“Q3 2022”) ⁽¹⁾. The related condensed interim consolidated financial statements and Management’s Discussion and Analysis for Q3 2022 are available on SEDAR at www.sedar.com and on CE Brands’ website at www.cebrands.ca. Q3 2022 HighlightsTotal Revenue in Q3 2022 was $1.5 million representing the third consecutive quarter of increasing revenue (Q2 2022 – $1.4 million and Q1 2022 – $1.1 million). The quarter over quarter increases in revenue from Q2 2022 were primarily a result of increased sales of baby monitors and initial sales of the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.